A LinkedIn post from ThinkCyte highlights an upcoming webinar held in collaboration with Scripps Research that will feature an onsite demo of the company’s VisionSort technology. The post describes how Dr. Romain Ballet plans to showcase VisionSort’s use of AI-driven cell morphology to identify cell states without traditional markers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the session will explore applications such as reconstructing lineage trajectories label-free, discovering disease-associated morphotypes, and running pooled CRISPR screens for complex phenotypes. For investors, this outreach suggests ThinkCyte is actively positioning VisionSort within advanced cell analysis, regenerative medicine, and drug discovery workflows, which could support technology validation, deepen academic and pharma engagement, and potentially expand its addressable market over time.